New drug ICP-538 tested in healthy people for first time
NCT ID NCT07535099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing the safety and tolerability of a new drug called ICP-538 in 104 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The goal is to gather basic safety information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ICP-538
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH SERVICES RESEARCH are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102200, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your local pharmacy become a hearing care hub?
- AI listens in to free up Doctors' time
- Survey reveals top priorities for Home-Based palliative care
- App aims to streamline doctor visits by letting patients log symptoms in advance
- Can better tracking improve addiction care? new study aims to find out
- What do mothers really need after early hospital discharge? new study aims to find out